New Frontiers in the Treatment and
Management of Relapsed/Refractory Multiple Myeloma: A Closer Look at
the Role of New and Emerging Therapies
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2020 Fall
Managed Care Forum. If you participated in the live session, you are
not eligible for continuing education credits from this archive.
This activity is valid from November 1, 2020 to March 1, 2022
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
Oncopeptides and Sanofi Genzyme
Multiple Myeloma (MM) accounts for 10% of hematologic malignancies.
In 2020, it is estimated that MM will be responsible for 12,960 new
deaths and 32,110 new cases. Multiple myeloma is a systemic
malignancy of plasma cells that is highly treatable but rarely
curable. It is potentially curable when it presents as a solitary
plasmacytoma of bone or as an extramedullary plasmacytoma. The
median survival in the prechemotherapy era was about 7 months. After
the introduction of chemotherapy, prognosis improved significantly
with a median survival of 24 months to 30 months and a 10-year
survival of 3%. There are several novel options currently undergoing
late stage clinical trials or regulatory review for relapsed or
refractory multiple myeloma that have shown great promise in their
ability to improve clinical outcomes. It is important that medical
directors, oncologists, nurse case managers and other healthcare
professionals are brought up to date on these emerging therapies and
how these options might be integrated into evolving treatment
paradigms in the management of relapsed/refractory multiple myeloma
Multiple Myeloma is staged by estimating the myeloma tumor cell mass
on the basis of the amount of monoclonal (or myeloma) protein (M
protein) in the serum and/or urine, along with various clinical
parameters, such as the hemoglobin and serum calcium concentrations,
the number of lytic bone lesions, and the presence or absence of
renal failure. The stage of the disease at presentation is a strong
determinant of survival. Treatment selection is influenced by the
age and general health of the patient, prior therapy, and the
presence of complications of the disease. Despite treatment advances
in the last several years, multiple myeloma remains a disease with
poor long-term survival as it is currently incurable and all
patients will eventually relapse, underlining the need for new
therapies. Fortunately for patients with MM, new options are
currently undergoing late stage clinical trials or regulatory
review, including novel peptide-drug conjugates that rapidly deliver
a cytotoxic payload into myeloma cells, which appear to improve
patient outcomes at a significant rate. It is critical that medical
directors, oncologists, pharmacy directors and nurses are updated
about these novel therapies.
Upon completion of this
activity, participants will be able to:
Differentiate the mechanism of
action, safety, and efficacy profiles of new and emerging
therapies for the treatment of relapsed/refractory multiple
Assess the role of new and emerging
anti-CD38 monoclonal antibodies and lipophilic
peptide-conjugated alkylators in the relapsed/refractory
multiple myeloma treatment paradigm
Understand best practices and
strategies for the selection of therapies for
relapsed/refractory MM based on patient risk stratification,
prior therapeutics regimens, and other clinical considerations
Explore managed care considerations
of new and emerging therapies by exploring where these agents
fit into current relapsed/refractory multiple myeloma management
Identify adverse events associated
with new and emerging therapies in relapsed/refractory multiple
myeloma, and select appropriate strategies to help ensure
patient treatment adherence and optimal quality of life
Examine factors driving the
discrepancy between real-world effectiveness of
relapsed/refractory multiple myeloma agents and clinical trial
||Kenneth C. Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Program Director, Jerome Lipper Multiple Myeloma Center
and LeBow Institute for Myeloma Therapeutics,
Dana-Farber Cancer Institute
Anderson serves as a consultant for Bristol-Myers
Squibb, Gilead Sciences, Janssen, Precision Biosciences,
Sanofi, Takeda, and Tolero. He owns stock in C4
Therapeutics and Oncopeptides. His presentation has been
peer reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
Oncopeptides and Sanofi Genzyme
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue